Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
Journal of Medical Sciences
  Year: 2007 | Volume: 7 | Issue: 7 | Page No.: 1192-1196
DOI: 10.3923/jms.2007.1192.1196
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Serum CA125; as a Diagnostic and Prognostic in Pediatric Lymphomas

A.M. Abdelmonem, Amany S. Elwakkad, Maysa T. Saleh and Saadia I. Muhammad

Abstract:
Elevated serum Cancer Associated Antigen 125 (CA125) levels have been reported in non-gynecologic tumors. Some adult studies showed that elevated CA125 levels correlate with advanced disease, poor response to treatment and lower survival rates. To evaluate CA125 levels in patients with Hodgkin’s Disease (HD) and Non-Hodgkin’s Lymphoma (NHL) and to investigate the correlations between CA125 levels, disease stage, pathology, response to therapy and outcome a 22 pediatric patients (9 with HD and 13 NHL) were prospectively studied. Serum CA125 assessment was done at diagnosis, during treatment and at end of therapy. CT scans of the chest, abdomen and pelvis were done at diagnosis, during and at end of therapy to document response. The correlations between serum CA125 levels and disease stage, pathology, response to therapy (documented by repeat CT scans of the involved sites) and outcome were statistically evaluated. Present results showed that the mean serum CA125 levels were elevated in 63.6% of children with lymphoma. While statistically significant more NHL patients showed abnormally elevated serum CA 125 (76.9% in NHL vs 44.4% in HD) p = 0.02, yet there was no significant difference regarding the magnitude of elevation in CA125 levels (p = 0.3). Significantly higher mean serum CA 125 levels were observed in patients with advanced stages (stage III, IV) p = 0.001. Mean CA 125 level significantly dropped in response to therapy with a mean diagnostic level of (143.45±168.05) compared to end of therapy mean level of (11.47±6.71) with p = 0.003. All patients with elevated CA125 at diagnosis who achieved complete remission had normalization of CA 125 by the end of therapy. On the contrary, none of those who failed therapy had a return of serum CA 125 to normal levels (p = 0.0003). None of patients who had normal serum CA125 succumbed to their disease compared to 3/14 (21.4%) who had high serum CA125 at diagnosis. As a conclusion we found that Serum CA125 is a useful tumor marker in pediatric patients with lymphomas. A high CA125 level at diagnosis correlates with advanced disease and poor outcome. Repeated CA125 measurements are useful in monitoring response to treatment.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

A.M. Abdelmonem, Amany S. Elwakkad, Maysa T. Saleh and Saadia I. Muhammad, 2007. Serum CA125; as a Diagnostic and Prognostic in Pediatric Lymphomas. Journal of Medical Sciences, 7: 1192-1196.

DOI: 10.3923/jms.2007.1192.1196

URL: https://scialert.net/abstract/?doi=jms.2007.1192.1196

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 

Curve Bottom